title: Epstein-Barr virus-induced lymphoproliferative disorder after rituximab combined with CHOP therapy.
abstract: We present the case of a 35-year-old woman with follicular lymphoma who developed an Epstein-Barr virus (EBV)-induced B-cell lymphoproliferation with secondary viral-induced hemophagocytosis 13 months after treatment with rituximab and CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy. The EBV-induced lymphoproliferation was successfully treated with single-agent rituximab. To our knowledge, this is the first such case reported in the literature. Herein, we briefly review the spectrum of immunodeficiency-associated lymphoproliferative disorders (LPDs), discuss the immune deficit induced by rituximab, and speculate on its possible association with EBV reactivation in this patient.
authors.affiliation: Department of Hematology, Hospices Civils de Lyon and University Claude Bernard, Lyon, France.
authors.forename: Anna
authors.initials: A
authors.lastname: Johnston
authors.forename: Gilles
authors.initials: G
authors.lastname: Salles
authors.forename: Daniel
authors.initials: D
authors.lastname: Espinouse
authors.forename: Pascale
authors.initials: P
authors.lastname: Felman
authors.forename: Patrice
authors.initials: P
authors.lastname: André
authors.forename: Françoise
authors.initials: F
authors.lastname: Berger
authors.forename: Bertrand
authors.initials: B
authors.lastname: Coiffier
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D020031:Epstein-Barr Virus Infections; D005260:Female; D006801:Humans; D051359:Lymphohistiocytosis, Hemophagocytic / Q000209:etiology*; D008224:Lymphoma, Follicular / Q000188:drug therapy*; D008232:Lymphoproliferative Disorders / Q000821:virology*; D011241:Prednisone / Q000008:administration & dosage; D000069283:Rituximab; D014750:Vincristine / Q000008:administration & dosage; D014775:Virus Activation
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone